Moderna’s Cancer Vaccine Success Doesn’t Live Up to Early Hype - WSJ — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna reported its mRNA cancer vaccine reduced the risk of melanoma recurrence by over 40% in a late-stage trial, marking a significant but not groundbreaking advance
- Merck co-developed the vaccine with Moderna and is supplying its drug Keytruda in the combination therapy, though a Merck exec called an early data leak 'unfortunate'
- Moderna stock extended losses as investors digested the trial results, indicating Wall Street had anticipated stronger efficacy or clearer commercial potential
- The Wall Street Journal assessed the outcome as falling short of early hype, tempering enthusiasm despite the positive clinical signal
- WIRED highlighted the 40%+ reduction in recurrence risk, framing the result as scientifically meaningful even if not transformative
Why it matters: Moderna needed a major win to justify its post-pandemic valuation, but the market's negative reaction suggests the melanoma data, while positive, doesn't guarantee commercial success or broader mRNA applicability. The 40% reduction is medically meaningful but may not be enough to shift oncology standards without survival benefit data.
Ask SkimNews
